A5027768049- Hematopoietic Stem Cell Transplantation
- Complement system in diseases
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Renal Diseases and Glomerulopathies
- Blood groups and transfusion
- Adenosine and Purinergic Signaling
- Hemoglobinopathies and Related Disorders
- Acute Lymphoblastic Leukemia research
- Iron Metabolism and Disorders
- T-cell and Retrovirus Studies
- Chronic Lymphocytic Leukemia Research
- Renal Transplantation Outcomes and Treatments
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Cutaneous lymphoproliferative disorders research
- Insurance, Mortality, Demography, Risk Management
- Vascular Procedures and Complications
- Restless Legs Syndrome Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Organ and Tissue Transplantation Research
- Organ Donation and Transplantation
- Obsessive-Compulsive Spectrum Disorders
- Schizophrenia research and treatment
- Mesenchymal stem cell research
University of Alabama at Birmingham
2025
University of Groningen
2024
Beatson West of Scotland Cancer Centre
2008-2020
Scottish National Blood Transfusion Service
2006-2020
Istituti Ospitalieri di Cremona
2012
Glasgow Royal Infirmary
2002-2008
Eastern State Hospital
1969
Atypical hemolytic uremic syndrome (aHUS) is a rare, possibly life-threatening disease characterized by platelet activation, hemolysis and thrombotic microangiopathy (TMA) leading to renal other end-organ damage. We originally conducted two phase 2 studies (26 weeks 1 year) evaluating eculizumab, terminal complement inhibitor, in patients with progressing TMA (trial 1) those long duration of aHUS chronic kidney 2). The current analysis assessed outcomes after years (median eculizumab...
Extracorporeal photopheresis (ECP) has been used for over 30 years in the treatment of erythrodermic cutaneous T-cell lymphoma (CTCL) and 20 chronic graft-versus-host disease (cGVHD). The lack prospective randomized trials led to different centres having patient selection criteria, schedules, monitoring protocols assessment criteria. ECP CTCL cGVHD is available only at six specialized across U.K. In recent Improving Outcomes Guidance National Institute Health Clinical Excellence endorsed use...
Extracorporeal photopheresis (ECP) has been used for over 35 years in the treatment of erythrodermic cutaneous T-cell lymphoma (CTCL) and 20 chronic acute graft-versus-host disease (GvHD) solid organ transplant rejection. ECP CTCL GvHD is available at specialised centres across UK. The lack prospective randomised trials led to development UK Consensus Statements patient selection, schedules, monitoring protocols assessment criteria ECP. recent literature reviewed considered when writing this...
The guideline group was selected to be representative of relevant UK-based medical and nursing experts. Systematic literature searches were conducted between September December 2012 using MEDLINE, OVID PLUS EMBASE for publications in English, keywords: plasma exchange; apheresis; exchange transfusion; extracorporeal photopheresis; lipoprotein leucocytapheresis; peripheral blood stem cells (PBSC); progenitor (PBPC) other keywords related the subsections this guideline. Relevant recent e.g....
Introduction: Cullen sign is an area of periumbilical ecchymosis that results from blood tracking along the round ligament. Any source retroperitoneal or abdominal hemorrhage can cause sign, but it often described in association with acute pancreatitis. Case Report: Here we report a case chronically ill male who presented bulging sensation his lower abdomen and pain. On physical examination this patient was noted to have large predominantly on left aspect umbilicus, consistent sign. Computed...
In Europe, the combination of plerixafor + granulocyte colony-stimulating factor is approved for mobilization hematopoietic stem cells autologous transplantation in patients with lymphoma and myeloma whose mobilize poorly. The purpose this study was to further assess safety efficacy front-line European or myeloma. multicenter, open label, single-arm study, received (10 μg/kg/day) subcutaneously 4 days; on evening day they were given (0.24 mg/kg) subcutaneously. Patients underwent apheresis 5...
Fludarabine and lenalidomide are essential drugs in the front-line treatment of non-Hodgkin lymphoma (NHL) multiple myeloma (MM), respectively. Data suggests that fludarabine therapy may have a deleterious effect on stem cell mobilization. In European compassionate use program, 48 patients (median age 57 years) previously treated with 5 cycles; range: 1-7 cycles) were given plerixafor plus granulocyte colony-stimulating factor (G-CSF) for remobilization following primary mobilization...
Thrombotic microangiopathies are rare conditions characterized by microangiopathic hemolytic anemia, microthrombi, and multiorgan insult. The disorders, which include uremic syndrome thrombotic thrombocytopenic purpura, often acute life threatening. We report a retrospective analysis of 65 patients presenting to our institution from 1997 2008 with all forms microangiopathy. Therapeutic plasma exchange was requirement for were referred institution; 66% female median age at presentation 52...
Acute thrombotic thrombocytopenic purpura (TTP) is a life-threatening emergency and plasma exchange (PEX) the initial treatment shown to reduce acute mortality.To compare current practice in United Kingdom (UK) against standards set out 2012 British Society of Haematology guideline, better understand issues affecting prompt initiation PEX.The trainee research network HaemSTAR conducted retrospective nationwide review adults presenting UK hospitals with first episode TTP.Data on 148 patients...
BACKGROUND: Plerixafor with granulocyte–colony‐stimulating factor (G‐CSF) has been shown to enhance stem cell mobilization in patients multiple myeloma and lymphoma previous failure. In this European named patient program we report the experience insufficiently mobilizing diagnosed nonhematologic diseases. STUDY DESIGN AND METHODS: Thirty‐three germ tumor (n = 11), Ewing sarcoma 6), Wiscott‐Aldrich disease 5), neuroblastoma 4), other diseases 7) were included study. was limited or current...
Summary. A phase I–II study of high‐dose (HD) alkylating agents in newly diagnosed patients with multiple myeloma after maximum response to Z‐Dex (idarubicin, dexamethasone) therapy and DHAP (cisplatin, HD cytosine arabinoside, dexamethasone), stem cell mobilization is reported. Twenty‐six patients, median age 56 years (range 42–66), completed chemotherapy peripheral blood cells (PBSC) were mobilized DHAP. Patients then preceded cyclophosphamide (HD Cy: 6 g/m 2 ) granulocyte...